Correlation of the activities of protein C, antithrombin and coagulation factor Ⅷ with the treatment of lung cancer with pulmonary embolism

doi:10.3969/j.issn.1673-8640.2014.10.003

Abstract

Abstract:

Objective To investigate the correlation of the activities of protein C(PC), antithrombin(AT) and coagulation factor Ⅷ(FⅧ) with the treatment of lung cancer with pulmonary embolism(PE). Methods A total of 98 patients with lung cancer and PE were enrolled as lung cancer with PE group. A total of 100 patients with lung cancer were enrolled as lung cancer group. Their sex and age were recorded, and lipoprotein(a)[Lp(a)], total cholesterol(TC), triglyceride (TG), C-reactive protein(CRP), thrombin time(TT), platelet (PLT) and fibrinogen(Fbg)in the 2 groups were determined, respectively. PC, AT, FⅧ and D-dimer were determined in lung cancer with PE group after 5-7 d of treatment. Logistic regression analysis was used to analyze the factors influencing coagulation-fibrinolysis after 5-7 d of treatment in lung cancer with PE group. The receiver operating characteristic(ROC) curve was used to analyze the diagnostic efficiency of these factors. Resutls Lp(a), TC, TG and TT in lung cancer with PE group were significantly higher than those in lung cancer group (P<0.05). The levels of PC, AT, FⅧ and D-dimer were significantly higher in lung cancer with PE group than those in lung cancer group (P<0.01).Logistic regression analysis and ROC curve analysis showed that PC, AT and FⅧ were influencing factors of coagulation-fibrinolysis after 5-7 d of treatment in lung cancer with PE group, and the areas under ROC curve were >0.90. Conclusions The influence of PC, AT and FⅧ on coagulation-fibrinolysis should be concerned in midterm treatment of lung cancer with PE, and their activities can be used to assess the therapeutic efficiency and treatment program in a given period.

Key words: Protein C, Antithrombin, Coagulation factor &, #x02167, Lung cancer, Pulmonary embolism

CLC Number:

R446.1

CHEN Huan, ZHANG Peng, LIU Junfeng. Correlation of the activities of protein C, antithrombin and coagulation factor Ⅷ with the treatment of lung cancer with pulmonary embolism[J]. , 2014, 29(10): 995-999.

References

[1] 林辛锋,王群,白春学,等. 肺癌合并慢性阻塞性肺疾病诊治概况调查[J]. 中华医学杂志,2011,91(40): 2815-2818.
[2] Cushman M. Epidemiology and risk factors for venous thrombosis[J]. Semin Hematol, 2007,44(2): 62-69.
[3] 中华医学会呼吸学分会. 肺血栓栓塞症的诊断与治疗指南(草案)[J]. 中华结核和呼吸杂志,2001,24(5):259-264.
[4] 王峻,周卫华,许林,等. 肺癌合并肺栓塞危险因素及预后的临床分析[J]. 中国肺癌杂志,2011,14(10):780-784.
[5] Pollack CV,Schreiber D,Goldhaber SZ,et al. Clinical characteristics,management,and outcomes of patients diagnosed with acute pulmonary embolism in the emergency department: initial report of EMPEROR (Multicenter Emergency Medicine Pulmonary Embolism in the Real World Registry)[J]. J Am Coll Cardiol,2011,57(6):700-706.
[6] 叶絮,刘晓力,冯莹,等. 蛋白C基因复合杂合突变导致的肺栓塞及家系研究[J]. 南方医科大学学报,2012,32(1):109-112.
[7] Somajo S,Koshiar RL,Norström E,et al. Protein S and factor V in regulation of coagulation on platelet microparticles by activated protein C[J]. Thromb Res, 2014, 134(1): 144-152.
[8] 付乃宽,陈永利,张敬霞,等. 急性肺栓塞患者溶栓治疗后凝血-纤溶指标的变化[J]. 中华血液学杂志,2007,28(3):206-208.
[9] 廖洪利,蒋小丽,田刚. 慢性阻塞性肺疾病急性加重期患者检测AT-Ⅲ的意义[J]. 现代检验医学杂志,2012,27(5):133-134.
[10] Wang YQ,Chen QL,Zhu D,et al. Portal vein thrombosis after aortic valve replacement surgery in a patient with antithrombin Ⅲ deficiency -case presentation[J]. J Cardiothorac Surg,2014,9(1):73.
[11] 王晓,朱均权.凝血因子Ⅴ、Ⅷ和组织因子与2型糖尿病合并冠心病的关系[J].检验医学,2014,29(1):34-37.
[12] 潘以锋,张皓. 静脉血栓栓塞症与凝血因子Ⅷ关系研究进展[J]. 中华实验外科杂志,2009,26(11):1579-1580.
[13] Payne AB,Miller CH,Hooper WC,et al. High factor Ⅷ, von Willebrand factor, and fibrinogen levels and risk of venous thromboembolism in blacks and whites[J]. Ethn Dis,2014,24(2):169-174.

[1]	ZHOU Yunlan, SHEN Lisong. Clinical application and challenges of liquid biopsy biomarkers in non-small cell lung cancer [J]. Laboratory Medicine, 2023, 38(9): 807-811.
[2]	FU Yi, YANG Xuesong, JIN Ligang, ZHAI Hongli, JIN Xiaoling. Correlation between small and dense low-density lipoprotein cholesterol and acute coronary syndrome with the occurrence of long-term adverse cardiovascular events [J]. Laboratory Medicine, 2023, 38(9): 878-883.
[3]	CHEN Ying, LI Wei, LIN Tao, YANG Li. Relationship between PFTK1 expression level and microvessel density and postoperative prognosis in non-small cell lung cancer [J]. Laboratory Medicine, 2023, 38(7): 634-639.
[4]	MA Jianguo, LI Hongchun. Correlation between blood lipid levels and cardiac function indexes in patients with coronary heart disease [J]. Laboratory Medicine, 2023, 38(7): 659-664.
[5]	YANG Zhongxin, LI Xiaoyu, CHEN Tao, CAO Wenjun. Roles of IL-8 and MMP-2 in the prognosis of non-small cell lung cancer patients after thoracoscopic segmentectomy [J]. Laboratory Medicine, 2023, 38(4): 342-346.
[6]	SONG Shiwei, LI Jingwu, LIN Tao, LIU Zeyu, WANG Zhiqiang, SUN Weidong. Relationship between GPNMB and non-small cell lung cancer immune infiltration and prognosis [J]. Laboratory Medicine, 2023, 38(4): 347-351.
[7]	SU Zhenzhen, ZOU Jihua, WANG Huimin, XU Weifeng, DING Fang, ZHANG Jingmei, WANG Zhanke. Consistency of serum LDL-P and LDL-C determination results [J]. Laboratory Medicine, 2023, 38(2): 148-152.
[8]	WU Ying, ZHANG Lihong, GAO Yin. Predictive value of high-density lipoprotein cholesterol on the risk of cerebral ischemic stroke in type 2 diabetes mellitus patients [J]. Laboratory Medicine, 2023, 38(11): 1052-1056.
[9]	XING Baobao, CAO Yinfang. Predictive value of sd-LDL-C/LDL-C ratio for in-stent restenosis in patients with AMI after interventional therapy [J]. Laboratory Medicine, 2023, 38(10): 941-945.
[10]	ZHANG Yifan, LI Changping, ZHANG Lili, CHEN Zhong. Relationship between plasma galectin 3 and low-density lipoprotein cholesterol stratified by ages in patients with cardiovascular disease [J]. Laboratory Medicine, 2023, 38(1): 8-13.
[11]	LIU Xingqiang, NING Lifen, LI Lin, CHEN Zhongcheng. Correlation of lung cancer clinicopathological characteristics with FR⁺-CTC,ANXA2 and ProGRP [J]. Laboratory Medicine, 2022, 37(8): 735-740.
[12]	ZHAO Mingna, ZHANG Chenzi, HONG Qiushuang, LOU Jiatao. Mechanism of IL-8/miR-182 positive feedback regulatory axis in non-small cell lung cancer [J]. Laboratory Medicine, 2022, 37(4): 349-355.
[13]	WANG Jianying, WANG Shanshan, ZHU Jun, HUANG Xiaochun, WAN Yuxiang, LIU Yun. Distribution and drug resistance of respiratory infection pathogens in patients with lung cancer after chemotherapy [J]. Laboratory Medicine, 2022, 37(4): 356-359.
[14]	XU Runhao, ZOU Chen, CAO Yun, CHEN Feng, LIU Yijing, ZHANG Shulin, ZHANG Jie. Roles of serum amino acid determinations in the diagnosis of early non-small-cell lung cancer [J]. Laboratory Medicine, 2022, 37(12): 1157-1163.
[15]	SHEN Ying, XU Xiaoping, ZHANG Lele, DU Yongping, MENG Chao. Clinical value of LDL-C determination in non-fasting blood samples [J]. Laboratory Medicine, 2022, 37(11): 1049-1056.